Boehringer Ingelheim has handed back the rights to a drug development project targeting pain and inflammation, ending a long-standing partnership with Orexo.
The FDA is wrestling with a host of issues surrounding highly addictive and often abused opioids and just recommended a drug that may provide some help in its effort.
Just three months after Titan Pharmaceuticals' experimental treatment for opioid addiction was red-flagged at the FDA, Orexo has cruised to an approval for a rival therapy.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
Sweden's Orexo has entered into an agreement with AstraZeneca regarding OX-CLI, a preclinical program for a new therapy to treat respiratory diseases.
AstraZeneca CEO Pascal Soriot is banking on a deep pipeline of respiratory meds to help revive the beleaguered drug giant.
Orexo's Japanese partner Kyowa Hakko has resubmitted Abstral, a sublingual fentanyl tablet that delivers the opioid drug under the tongue for the treatment of breakthrough cancer pain, for marketing approval in Japan.
Orexo, a Swedish pharma company, has submitted to the FDA a new drug application for Zubsolv (OX219), its under-the-tongue formulation of buprenorphine and naloxone for treatment of opioid dependence. The drug uses Orexo's sublingual drug delivery technology.
Sweden's Orexo will slash jobs and focus on three development programs that rely on enhancing already-approved treatments.
Sweden's Orexo is pocketing $10 million from an upfront payment it will reap as part of a three-year, $585 million development pact with J&J's drug arm. The collaboration centers on preclinical